Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Cash & Equivalents (2017 - 2026)

AdaptHealth has reported Cash & Equivalents over the past 9 years, most recently at $106.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 3.29% year-over-year to $106.1 million; the TTM value through Dec 2025 reached $106.1 million, down 3.29%, while the annual FY2025 figure was $106.1 million, 3.29% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $106.1 million at AdaptHealth, up from $80.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $336.7 million in Q3 2021 and troughed at $45.1 million in Q2 2023.
  • A 5-year average of $107.0 million and a median of $100.8 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 174.35% in 2021 and later tumbled 69.08% in 2022.
  • Year by year, Cash & Equivalents stood at $149.6 million in 2021, then tumbled by 69.08% to $46.3 million in 2022, then soared by 66.69% to $77.1 million in 2023, then skyrocketed by 42.28% to $109.7 million in 2024, then fell by 3.29% to $106.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for AHCO at $106.1 million in Q4 2025, $80.4 million in Q3 2025, and $68.6 million in Q2 2025.